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Abstract
Background: Anti-fibrotic drugs such as pirfenidone have been developed for the treatment of idiopathic
pulmonary fibrosis. Because activated fibroblasts in inflammatory conditions have similar characteristics as
cancer-associated fibroblasts (CAFs) and CAFs contribute actively to the malignant phenotype, we believe that
anti-fibrotic drugs have the potential to be repurposed as anti-cancer drugs.
Methods: The effects of pirfenidone alone and in combination with cisplatin on human patient-derived CAF cell
lines and non-small cell lung cancer (NSCLC) cell lines were examined. The impact on cell death in vitro as well as
tumor growth in a mouse model was determined. Annexin V/PI staining and Western blot analysis were used to
characterize cell death. Synergy was assessed with the combination index method using Calcusyn software.
Results: Pirfenidone alone induced apoptotic cell death in lung CAFs at a high concentration (1.5 mg/mL).
However, co-culture in vitro experiments and co-implantation in vivo experiments showed that the combination of
low doses of cisplatin (10 μM) and low doses of pirfenidone (0.5 mg/mL), in both CAFs and tumors, lead to
increased cell death and decreased tumor progression, respectively. Furthermore, the combination of cisplatin and
pirfenidone in NSCLC cells (A549 and H157 cells) leads to increased apoptosis and synergistic cell death.
Conclusions: Our studies reveal for the first time that the combination of cisplatin and pirfenidone is active in
preclinical models of NSCLC and therefore may be a new therapeutic approach in this disease.
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Background
Cellular transformation to neoplasm, tumor formation,
and progression require an inherent crosstalk between the
tumor microenvironment and the tumor. The tumor
microenvironment or tumor stroma comprises various
cell types, including cancer-associated fibroblasts (CAFs),
immune cells, endothelial cells, and mesenchymal cells. In
this heterogeneous environment, CAFs are the most
prominent cell type and are known to be key contributors
to tumor progression, invasion, and metastasis [1]. In
addition, functionally, they are known to secrete extracel-
lular matrix proteins (e.g., collagen I, III, IV), chemokines
(e.g., interleukin 6, CXCL8, CXCL12), cytokines (e.g.,
interleukin 6 and interleukin 8), and tumor growth factors
(e.g., vascular endothelial-derived growth factor, trans-
forming growth factor beta (TGFβ), hepatocyte growth
factor, epidermal growth factor, and fibroblast growth fac-
tor] [2, 3]. Contact between CAFs and tumor cells have
shown increased tumor cell survival via the activation of
anti-apoptotic pathways or by induction of the epithelial
to mesenchymal transition in melanoma and non-small
cell lung cancer (NSCLC) [2, 4–6]. Therefore, a combined
therapy that targets both the tumor cell and the CAFs
might lead to novel therapies in cancer.
Pirfenidone [5-methyl-1-phenyl-2(1H)-pyridone] is a
well-recognized anti-fibrotic compound shown to be ef-
fective in various in vivo models [7–9] and in clinical tri-
als [10]. In addition, it is endowed with anti-proliferative
effects in a variety of cells, spanning from human Tenon
fibroblasts [11], cardiac fibroblasts [12], leiomyoma cells
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[13], lung fibroblasts [14], pancreatic stellate cells, and
pancreatic cancer cells [15]. Furthermore, it has been
shown that pirfenidone inhibits proliferation, migration,
and epithelial-mesenchymal transition of a human epi-
thelial cell line [16], disrupted tumor-stromal interac-
tions in pancreatic cancer [15], and inhibited TGFβ1-
induced overexpression of collagen type I in A549 cells
[17]. In 2011, pirfenidone was the first drug approved in
Europe for the treatment of idiopathic pulmonary fibro-
sis [18] following its approval in the United States in
2014. Various groups have shown changes in different
cytokines and growth factors such as platelet-derived
growth factor-A, hepatocyte growth factor, and periostin
in pancreatic stellate cells [15], heat shock protein 47 in
lung cancer cells [17], TGFβ1 in cardiac fibroblasts [12],
and COX-2 and PGE2 in orbital fibroblasts [19]; how-
ever, the mechanism by which it exerts its effects is yet
to be elucidated.
Cisplatin is a platinum-based chemotherapeutic drug
that has been used as the standard of care in late stages
of NSCLC in combination with paclitaxel, vinorelbine,
gemcitabine, docetaxel, pemetrexed, or irinotecan [20].
Although the combination of cisplatin and other chemo-
therapeutic drugs has been successful in increasing the
survival rate in some patients, the overall response rate
remains partial and many do not respond to this com-
bination [20, 21]. Cisplatin is known to intercalate DNA
by the formation of cross-links. The damage done by
cisplatin leads to inhibition of DNA replication followed
by apoptosis or necrosis [20, 22]. Studies have exten-
sively shown the effects of cisplatin in tumor cells, but
only a small percentage of studies interrogate its effects
on CAFs. Sonnenberg et al. [23] was the first to show
that CAFs resected from breast and lung patients had a
high variable sensitivity to cisplatin treatment compar-
able to that of tumor cell lines. Moreover, when co-
cultured, they observed that lung cancer cells were more
sensitive to cisplatin than CAFs.
Here, we further characterized the effects of pirfeni-
done in the tumor microenvironment. In this study, we
demonstrated that the combination of pirfenidone and
cisplatin suppressed the proliferation of NSCLC cells
and CAFs. In addition, we examined the effect of pirfeni-
done and cisplatin in a co-culture model and in an in
vivo model using both NSCLC cells and CAFs derived
from lung tumor and showed that the combination of
pirfenidone and cisplatin has a detrimental effect in both
cell populations by the activation of the apoptotic
machinery.
Methods
Cell culture and reagents
Primary human fibroblasts were isolated from portions
of lung tumors resected from adult patients for clinically
indicated reasons. Patients had provided written in-
formed consent to allow use of tumor samples. Our
study received approval from University of South Florida
Internal Review Board (Pro00015693). The tumors were
mechanically and enzymatically (collagenase, protease,
and DNase) digested, and the cells were cultured in
RPMI, 10 % FBS, PenStrep (Life Technologies), and L-
glutamine at 37 °C. After 1 week of culture, tumor and
immune cells died; however, the CAFs proliferated vigor-
ously and survived for greater than 15 passages. To ver-
ify whether cells were actually CAFs, an α-smooth
muscle actin Western blot analysis was performed, as
well as a flow cytometric analysis after staining with
anti-FAP [24]. A549, H157, H2122, H358, H1299, H23
and PC9 cells were purchased from American Type Cul-
ture Collection (Manassas, VA) and cultured in RPMI,
10 % FBS, PenStrep, and L-glutamine at 37 °C. Pirfeni-
done was purchased from TCI America, and cisplatin
was obtained from TEVA.
Morphologic analysis
To examine the morphology of cultured cells after treat-
ment with pirfenidone, 3 × 105 CAF cells/well were
seeded in a 6-well culture plate in RPMI. After 24 h, the
cells were treated with 1.5 mg/mL of pirfenidone or ve-
hicle control for 48 h. Pictures were taken under a
brightfield light with an automated Zeiss Observer Z.1
inverted microscope as described before [24].
Annexin V/PI analysis
To examine apoptotic cell death, 1.5 × 105 cells/well
CAFs or NSCLC cells were seeded into 6-well culture
plate in RPMI. After 24 h the cells were treated with pir-
fenidone at either 0.5 mg/mL or 1.5 mg/mL, 10 μM cis-
platin, or vehicle control. Supernatant and cells were
collected 24 and 48 h later. The adherent cells were re-
moved from the plate using 250 μL trypsin (Invitrogen)
and allowed to rest in complete media for 15 min.
Annexin V/PI analysis was performed as described be-
fore [24].
Cell viability assay
The CellTiter 96® AQueous One Solution cell prolifera-
tion assay (MTS, Promega) was used to examine cell via-
bility. Cells were seeded into 96-well plates at 5 × 103
cells/well. They were pretreated with U0126 at 10 μM
(Cell Signaling; 9903) and then treated with escalating
doses of pirfenidone or with 0.5 mg/mL of pirfenidone
and 10 μM of cisplatin for 72 h. After the treatment
period, 20 μL of the MTS solution was added and incu-
bated at 37 °C for 1 h. Plates were read at 490 nm in a
BioTek EL808 microplate reader. Treatments were com-
pared to their vehicle control.
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Caspase 3/7 activity assay
The CellPlayer 96-well kinetic caspase 3/7 reagent
(Essen Bioscience) was used to assess caspase 3/7 activ-
ity. CAF cells were seeded in a 96-well plate at 5 × 103
cells/well. They were pre-treated with Z-VAD.fmk
(50 μM) and then treated with pirfenidone (1.5 mg/mL)
for 48 h. After treatment, the CellPlayer 96-well kinetic
caspase 3/7 reagent was added to the cells at a final con-
centration of 5 μM. The caspase 3/7 activity assay was
performed as described before [24].
TGFβ1 ELISA
TGFβ1 secretion by CAFs was determined. CAFs were
seeded in 6-well plates at 1.5 × 105 cells/well. After 24 h,
the cells were treated with pirfenidone (1.5 mg/mL) or
control agent for 72 h. The supernatant was collected
and a TGFβ1 ELISA (Roche) was performed per manu-
facturer’s instructions.
Synergy proliferation assay
The activity levels of drugs alone and in combination
were determined by a high-throughput CellTiter-Blue
(Promega) cell viability assay. Cells (1.2–2 × 103) were
plated in each well of 384-well plates using a Precision
XS liquid handling station (Bio-Tek Instruments, Inc.)
and incubated overnight. A liquid handling station was
used to serially dilute all drugs in media, and 5 μL were
added to 4 replicate wells and an additional 4 control
wells received a diluent control without drug. At the end
of the incubation period with drugs, 5 μL of CellTiter-
Blue reagent were added to each well. The fluorescence
of the product of viable cells was measured with a Syn-
ergy 4 microplate reader (Bio-Tek Instruments, Inc). We
determined IC50 values using a sigmoidal equilibrium
model regression and XLfit version 5.2 (ID Business So-
lutions Ltd.). The IC50 values obtained from single-drug
cell viability assays were used to design subsequent drug
combination experiments.
Synergy analysis
The effect of drug combination was evaluated using Cal-
cusyn software (Biosoft). The synergy experiment was
performed as described above, and the results were ana-
lyzed for synergistic, additive, or antagonistic effects
using the combination index (CI) method developed by
Chou and Talalay [25], with CI < 1, CI = 1, and CI > 1 in-
dicating synergism, additive effects, and antagonism, re-
spectively. A confidence interval of 0.1–0.3 meant strong
synergism, 0.3–0.7 indicated synergism, 0.7–0.85 indi-
cated moderate synergism, 0.85–0.90 indicated slight
synergism, and 0.90–1.10 indicated nearly additive.
Co-culture model
A549 cells were stained using Cell Tracker Violet (Invi-
trogen) per manufacturer’s instructions. Briefly, in a 100-
mm dish, stained A549 cells and unstained CAFs were
co-seeded at 2.5 × 105 cells/plate. After 24 h, the cells
were treated and then harvested after 48 h of treatment.
Annexin V/PI analysis was performed as described be-
fore on each cell line, which was determined by their
Cell Tracker Violet status, positive (A549) or negative
(CAF) to the stain.
Mouse model
A549 cells (4 × 106) and CAFs (4 × 106) were injected
subcutaneously into 4- to 6-week-old athymic nude mice
(NCI). When tumors were palpable, mice were randomly
allocated into 4 groups and treated with daily intraperi-
toneal injections of (1) control vehicle (H2O); (2) pirfeni-
done alone (200 mg/kg; dissolved in H2O) for 27 days;
(3) cisplatin alone (5 mg/kg) on days 0, 3, 6, 21, 24, and
27; or 4) pirfenidone and cisplatin as described above.
The experiment was terminated when tumors reached
200 mm2 or became ulcerated.
Ethics and permissions
Animal experiments were performed according to a
protocol approved by the Institutional Animal Care and
Use Committee of the University of South Florida.
Western blots
Whole cell lysates were collected in 1X CHAPS buffer
(Cell Signaling), from pirfenidone-treated A549 cells as
well as a human CAF line. Protein concentrations were
quantified using the Bio-Rad protein assay dye. Equal
amounts of protein (40 μg) were loaded into the wells of
a 10 % SDS-PAGE gel and resolved at 100 V for 90 min.
Proteins were then transferred to a PVDF membrane,
blocked, and then probed for PARP (Cell Signaling;
9542) at 1:2000, phospho-44/42 MAPK (Erk1/2) (Cell
Signaling; 4370) at 1:2000, p44/42 MAPK (Erk1/2) (Cell
Signaling; 9102) at 1:2000, phospho-Akt (Cell Signaling;
9271) at 1:2000, and Akt (Cell Signaling; 4691) at 1:2000,
with an overnight incubation at 4 °C. GAPDH was used
at 1:2000 concentration for 30 min at room temperature
(Cell Signaling; 2118S). All of the primary antibodies
were incubated afterward with anti-rabbit IgG horserad-
ish peroxidase (Cell Signaling; 7074) at 1:2000 for
30 min at room temperature.
Statistical analysis
Data are shown as means ± SE. Statistical calculations
were performed using Student t test. Statistical signifi-
cance was accepted as P values less than 0.05.
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Results
Pirfenidone induces apoptosis in CAFs
Pirfenidone has been reported to have inhibitory effects
on fibroblast proliferation [7, 11, 12, 14]. However, the
effects of pirfenidone in lung CAFs have yet to be ex-
plored. To determine whether pirfenidone has any effect
on lung CAFs, a proliferation assay was performed with
varying concentrations of the drug. Figure 1a shows that
high concentrations of pirfenidone (1.5 mg/mL) result in
a 40 % decrease in lung CAF proliferation, which was
not observed at any other concentration. A morpho-
logical analysis (Fig. 1b) also illustrates the effects of the
drug on decreasing the number of lung CAFs. To
characterize the effect of pirfenidone on lung CAFs, we
performed various apoptotic assays. An annexin V/PI
analysis (Fig. 1c) was performed on lung CAFs treated
with pirfenidone (1.5 mg/mL). The results indicated an
increase in early apoptosis (annexin V+/PI-; lower right
panel) and late apoptosis (annexin V+/PI+; upper right
panel) after 72 h of treatment. In 3 independent experi-
ments, the average percentage of early apoptotic cell
death in the treated cells (15.8 %) was statistically signifi-
cant (P = 0.02) when compared to its untreated control
(5 %) (Fig. 1d). In addition, in a caspase 3/7 analysis per-
formed using the CellPlayer 96-well kinetic caspase 3/7
reagent, an almost 3-fold increase in caspase 3/7 was ob-
served in CAFs treated with pirfenidone when compared
to its control (Fig. 1e). These results suggest that high
concentration of pirfenidone cause the activation of the
apoptotic pathway in lung CAFs leading to cell death.
Pirfenidone reduces TGFβ1 expression
Pirfenidone has been shown to reduce the secretion of
TGFβ1 by some cell types [26–28]. To determine
whether pirfenidone has the same effect on lung CAFs,
we treated the cells with pirfenidone (1.5 mg/mL), and
measured the amount of TGFβ1 secreted over 72 h de-
termined by ELISA. Figure 2a shows that there was a de-
crease in TGFβ1 secretion when lung CAFs were treated
with pirfenidone. To determine whether this had an ef-
fect on survival of the lung CAFs, a proliferation assay
was performed with and without pirfenidone, in the
presence and absence of recombinant human TGFβ1
(rhTGFβ1; 5 ng/mL). The addition of rhTGFβ1 did not
significantly increase the proliferation in lung CAFs
(Fig. 2b). Thus, addition of rhTGFβ1 does not significantly
Fig. 1 a MTS assay showing the viability of lung CAFs after 72-h treatment with varying doses of pirfenidone. b Morphological analysis after 72 h
of treatment with 1.5 mg/mL pirfenidone shows decreased cell numbers versus control. c Representative annexin V/PI flow cytometric analyses in
lung CAFs after 48 h of treatment showing increased apoptosis in pirfenidone (1.5 mg/mL)-treated lung CAFs versus control. d Average of 3
independent annexin V/PI experiments in lung CAFs. e Active caspase 3/7 assay showing increased active caspase 3/7 in lung CAFs after 48 h of
treatment with pirfenidone (1.5 mg/mL). *P < 0.05
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protect these cells from pirfenidone-induced cell death.
Therefore, it may be that TGFβ1 is a redundant pathway
by which pirfenidone induces cell death, but it is not the
main pathway involved.
Co-culture model shows increased cell death in
combination treatment
To better understand whether pirfenidone has an effect
in the tumor microenvironment, a two-dimensional cell
culture model combining lung CAFs and NSCLC A549
cells was utilized, allowing us to observe a more physio-
logically relevant model of how a tumor may behave in
vivo. This model enables the cross-talk between the
tumor cells and the lung CAFs, which are important
components of the tumor microenvironment in vitro.
Furthermore, this model was designed to determine
whether pirfenidone, targeting the CAFs, in combination
with a known chemotherapeutic agent, cisplatin, could
lead to a more robust increase in cell death. Combin-
ation studies using various concentrations of both drugs
were performed. The combination that produced the
best results was pirfenidone at 0.5 mg/mL and cisplatin
at 10 μM. To differentiate both cell lines, for the flow
cytometric analysis, the A549 cells were stained with
Cell Tracker Violet® before the cells were co-cultured.
We found that the combination of both drugs led to a
significant increase in annexin V+/PI+ (dead) population
versus control (Fig. 3) or pirfenidone or cisplatin alone
(data not shown) in both the lung CAFs and the A549
cells. Thus, the combination of pirfenidone with cis-
platin showed an effect on both the tumor cells and the
lung CAFs.
In vivo model of A549 and CAF leads to reduced tumor
growth
We used an in vivo model to corroborate the data ob-
tained with the in vitro co-culture model. Nude mice
were inoculated with a combination of A549 cells and
lung CAF cells at a 1:1 ratio. Treatment with pirfenidone
(200 mg/kg) and cisplatin (5 mg/kg) began as soon as
the tumors were palpable. Pirfenidone was given daily
for a total of 27 days, whereas cisplatin was given once
every 3 days at the beginning of treatment and at the
end of treatment. Mice were kept for an additional
16 days after treatment to observe tumor growth.
Figure 4a shows the size of the tumors after the start of
the treatment until the end of the study on day 43.
There was no difference in the growth rate of tumors in
untreated, cisplatin-treated, or pirfenidone-treated mice.
However, the combination of cisplatin and pirfenidone
produced a significant decrease in tumor growth
(Fig. 4b).
Pirfenidone is synergistic with cisplatin in producing cell
death
Our previous data demonstrated that the combination
treatment significantly decreased cell viability and re-
duced tumor volume in lung CAFs and tumor cells.
Next, we investigated whether the combination of pirfe-
nidone and cisplatin had an effect on NSCLC cell lines
in an in vitro model. A proliferation assay was per-
formed using 7 NSCLC cell lines (only A549 is shown)
in the presence of cisplatin (10 μM) and pirfenidone
(0.5 mg/mL) for 72 h. We observed a small decrease in
cell proliferation in the presence of pirfenidone alone
(20 %), as well as with cisplatin alone (10 %) (Fig. 5a). As
predicted, when both drugs were combined, we observed
a significant decline in proliferation (60 %). Additionally,
we examined 6 different NSCLC cell lines using the
treatment regimen described above. Interestingly, 3 of 6
cell lines showed decreased proliferation in the combin-
ation treatment (Additional file 1). To characterize the
type of cell death induced by pirfenidone and cisplatin,
we performed an annexin V/PI flow cytometric analysis
and showed that the combination of both drugs increased
Fig. 2 a TGFβ ELISA in lung CAFs treated for 72 h with pirfenidone (1.5 mg/mL). Decreased TGFβ is observed in lung CAFs in the presence of
pirfenidone. b MTS assay showed viability of lung CAFs after 72-h treatment with pirfenidone (Pirf; 1.5 mg/mL) in the presence and absence of
rhTGFβ (TGFβ, 5 ng/mL). *P < 0.05
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the percentage of early apoptotic cell death when com-
pared to single-drug treatment alone (Fig. 5b). In addition,
immunoblotting analysis of PARP cleavage demonstrated
that there was an increase of the 89-kDa fragment
(indicating apoptosis) in the combination when compared
to the single-drug treatments (Fig. 5c).
To determine whether the effects of the combination
of pirfenidone and cisplatin were synergistic, we treated
A549 and H157 cells with various concentrations of pir-
fenidone and cisplatin in a constant 1:50 ratio and used
Calcusyn software to generate Fa-Cl plots. Figure 6a and
b show the specific treatment concentrations in which
the combination index values were above and below 1,
indicating antagonistic and synergistic interactions, re-
spectively. Our results show that the combination of pir-
fenidone and cisplatin was synergistic in both A549 and
H157 NSCLC cells.
To explore the mechanism of this synergy, we exam-
ined the TGFβ signaling pathways because previous
studies [24–26] have suggested that pirfenidone de-
creases TGFβ1 expression. We found no significant
changes in proteins involved in the canonical pathway of
TGFβ; specifically, cisplatin plus pirfenidone had no ef-
fect on phosphorylated Smad-2, β-catenin, and Snail
(data not shown). However, we found the non-canonical
TGFβ signaling pathway involving ERK and AKT was af-
fected by cisplatin plus pirfenidone. An increase in phos-
phorylated ERK was observed at an early time point
(15 min after treatment), whereas no changes in phos-
phorylated Akt were observed when pirfenidone and cis-
platin were used in combination. Interestingly, a
decrease in phosphorylated Akt became evident at a
much later time point (48 h) when both drugs were
used in combination, compared to single drug alone
(Additional file 2). These studies suggest the possibil-
ity that the ERK pathway may play an integral role in
the increased cell death observed in the combination
treatment, since the changes were observed at a very
early time point after treatment. To further explore
this possibility, we inhibited the phosphorylation of ERK
with the MEK inhibitor U0126. When A549 cells were
treated with the inhibitor (10 μM) for 1 h before treatment
was started, viability at 72 h was not influenced by cis-
platin and pirfenidone (Additional file 3). These findings
suggest that, although the ERK pathway is affected by cis-
platin and pirfenidone, it is not the main pathway by
which these drugs induce cell death in NSCLC.
Discussion
Given the fact that CAFs actively contribute to the ma-
lignant phenotype, targeting these cells in cancer pa-
tients could produce clinical benefit. CAFs share a
number of characteristics with fibroblasts that produce
fibrosing diseases such as idiopathic pulmonary fibrosis.
Several drugs have recently been approved for the treat-
ment of this disease and could be repurposed as anti-
cancer drugs by targeting CAFs. We demonstrated that
one of these drugs, pirfenidone, could result in CAF
death but only at high concentrations. However, in com-
bination with cisplatin, lower concentrations produced
Fig. 3 Lung CAFs and A549s were co-cultured at a 1:1 ratio. A549s
were stained in to distinguish between the 2 different cells. Annexin
V/PI flow cytometric analysis was performed after 48 h of treatment
with cisplatin (10 μM) and pirfenidone (0.5 mg/mL). Data show an
increase in dead cells (annexin V+/PI+) with combined treatment
(CP) when compared to the control (Ctrl) in both cell types. *P < 0.05
A B
Fig. 4 In vivo nude mouse model of lung CAFs and A549 (1:1) treated intraperitoneally with 200 mg/kg pirfenidone (Pirf; day 0–27) and 5 mg/kg
cisplatin (Cis; day 0, 3, 6, 21, 24, 27) or the combination of both drugs. a Graph of the tumor measurements throughout the entire study. b Scatter plot
on last day (day 43) of tumor measurements. Each group consisted of 5 mice. The experiment was done twice with similar trends. *P < 0.05
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CAF death. Surprisingly, we also found that pirfenidone
has a direct effect on NSCLC tumor cells and therefore
has the potential of functioning as an anti-cancer drug
by affecting both CAFs and tumor cells.
The exact mechanism of action of pirfenidone is still un-
known. Numerous studies have shown that pirfenidone
plays a role in the regulation of TGFβ as well as MMP, but
the precise mechanism by which the drug exerts its anti-
proliferative effect in fibroblasts remains unknown. Here,
we demonstrated that pirfenidone decreases TGFβ1 levels;
however, the addition of rhTGFβ1 did not rescue the lung
CAFs from cell death, indicating that there are other
unknown pathways involved. In the tumor cells, the non-
canonical TGFβ signaling pathway was affected, although
functional inhibition of the pathway failed to abrogate its
ability to produce cell death.
Other investigators have studied the strategy of com-
bining pirfenidone with chemotherapy. Kozono et al.
[15] showed that pirfenidone affects tumor-stromal in-
teractions between pancreatic stellate cells and pancre-
atic cancer cells in vitro. In addition, they showed that
the combination of pirfenidone with gemcitabine inhib-
ited the growth of the tumors in an in vivo model of




Fig. 5 a MTS assay showing the viability of A549 after 72-h treatment with a low dose of cisplatin (Cis; 10 μM) and a low dose of pirfenidone
(Pirf; 0.5 mg/mL). Untrt, untreated. b Annexin V/PI flow cytometric analysis in A549 cells after 48 h of treatment showing increased apoptosis
when agents were combined (cisplatin + pirfenidone) compared with control. c Immunoblot analysis of PARP cleavage showing significant PARP
cleavage in the combination of both drugs when compared to each drug alone. *P < 0.05
A B
Fig. 6 Activity of the combination of cisplatin and pirfenidone was determined using the CellTiter-Blue cell viability assay after a 72-h treatment
in A549 cells (a) and H157 cells (b). Results were analyzed for synergism using the combination index (CI) method. A confidence interval of
0.1–0.3 indicated strong synergism, 0.3–0.7 indicated synergism, 0.7–0.85 indicated moderate synergism, 0.85–0.90 indicated slight synergism, and
0.90–1.10 indicated nearly additive
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stellate cells. Recently, Choi et al. [29] showed that the
combination of sunitinib and pirfenidone led to in-
creased radiosensitivity of NSCLC tumors in vivo. Our
study is the first to show that the combination of pirfeni-
done and cisplatin, as demonstrated in a co-culture
model as well as in an in vivo model, leads to increased
cell death and tumor regression in NSCLC.
Conclusions
Although the mechanism is as yet uncertain, the anti-
fibrotic drug pirfenidone used in the treatment of idio-
pathic pulmonary fibrosis, when combined with cis-
platin, produces CAF and surprisingly tumor cell death.
This suggests a new strategy for the treatment of cancer,
repurposing this drug to kill the tumor-promoting CAFs
and the tumor cells themselves, which may produce a
clinical benefit greater than would be expected with
chemotherapy alone.
Additional files
Additional file 1: MTS assay showing the viability of H358 (A),
H1299 (B), H23 (C), H157 (D), H2122 (E), and PC9 (F) after 72-h
treatment with a low dose of cisplatin (Cis; 10 μM) and a low dose
of pirfenidone (Pirf; 0.5 mg/mL). * P < 0.05. (PDF 1253 kb)
Additional file 2: Immunoblot analysis shows an increase in
phosphorylated ERK when A549 cells are treated with low doses of
cisplatin (10 μM) and low doses of pirfenidone (0.5 mg/mL) at early
time points (15 and 30 min; A) when compared to each drug alone.
B: At 48 h after treatment, there is a decrease in phosphorylated Akt
when compared to each drug alone. (PDF 1211 kb)
Additional file 3: MTS assay showing the viability of A549 cells
after 72-h treatment with a low dose of cisplatin (Cis; 10 μM) and
low dose of pirfenidone (Pirf; 0.5 mg/mL) in the presence and
absence of the MEK inhibitor U0126 (U; 10 μM). (PDF 3219 kb)
Abbreviations
CAFs: cancer associated fibroblasts; CI: combination index; NSCLC: non-small
cell lung cancer; rhTGFβ1: recombinant human TGFβ1; TGFβ: transforming
growth factor beta.
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